[1] 国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志:电子版,2018,10(6):1-130.
[2] BREET N J, VAN J W, BOUMAN H J, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA, 2010, 303(8):754-762.
[3] JIA D M, CHEN Z B, ZHANG M J, et al. CYP2C19 polymorphisms and antiplatelet effect of clopidogrel in acute ischemic stroke in China[J]. Stroke,2013,44(6):1717-1719.
[4] HOLMES D R, DEHMER G J, KAUL S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons [J]. J Am Coll Cardiol,2010,56(4):321-341.
[5] KLEIN M D, LEE C R, STOUFFER G A. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions[J]. Pharmacogenomics,2018,19(13):1039-1046.
[6] FERRI N, CORSINI A, BELLOSTA S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties[J]. Drugs, 2013, 73 (15):1681-1709.
[7] ELLIS K J, STOUFFER G A, MCLEOD H L, et al. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations[J]. Pharmacogenomics,2009,10(11):1799-1817.
[8] DE MORAIS S M, WILKINSON G R, BLAISDELL J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem,1994,269(22):15419-15422.
[9] SHULDINER A R, CONNELL J R, BLIDEN K P, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA,2009,302(8):849-857.
[11]MEGA J L, SIMON T, COLLET J P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis[J]. JAMA,2010,304(16):1821-1830.
[12]HOLMES M V, PEREL P, SHAH T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis[J]. JAMA,2011,306(24):2704-2714.
[13]CAVALLARI L H, LEE C R, BEITELSHEES A L, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention[J]. JACC Cardiovasc Interv,2018,11(2):181-191.
[14]NOTARANGELO F M, MAGLIETTA G, BEVILACQUA P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: The PHARMCLO Trial[J]. J Am Coll Cardiol,2018,71(17):1869-1877.
[15]CAYLA G, CUISSET T, SILVAIN J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial[J]. Lancet, 2016, 388(10055):2015-2022.
[16]ELLIS K J, STOUFFER G A, MCLEOD H L, et al. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations[J]. Pharmacogenomics,2009,10(11):1799-1817.
[17]WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N EngI J Med, 2007, 357(20):2001-2015.
[18]JAMES E T, STEVEN M M. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients[J]. Am J Cardiovasc Drugs,2012, 12(2):83-91.
[19]WALLENTIN L, BECKER R C, BUDAJ A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N EngI J Med, 2009, 361(11):1045-1057.
[20]DAYOUB E J, SEIGERMAN M, TUTEJA S, et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016[J]. JAMA Intern Med,2018,178(7):943-950.
[21]PRICE M J, BERGER P B, TEIRSTEIN P S, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J]. JAMA,2011,305(11):1097-1105.
[22]MEGA J L, HOCHHOLZER W, FRELINGER A L, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA, 2011, 306(20):2221-2228. |
